Similar articles

• Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge".

  Belkacémi Y, Gligorov J. Belkacémi Y, et al. Radiother Oncol. 2010 Jan;94(1):119-20; author reply 120-1. doi: 10.1016/j.radonc.2009.04.009. Epub 2009 May 4. Radiother Oncol. 2010. PMID: 19410315 No abstract available.
• [The clinical relevance of the overexpression of HER-2 in breast cancer].

  Khosravi Shahi P, Pérez Manga G. Khosravi Shahi P, et al. An Med Interna. 2006 Mar;23(3):103-4. doi: 10.4321/s0212-71992006000300001. An Med Interna. 2006. PMID: 16737428 Spanish. No abstract available.
• [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].

  Belkacémi Y, Laharie-Mineur H, Gligorov J, Azria D. Belkacémi Y, et al. Cancer Radiother. 2007 Sep;11(5):266-75. doi: 10.1016/j.canrad.2007.04.002. Epub 2007 Jul 20. Cancer Radiother. 2007. PMID: 17644449 Review. French.
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Clinical Trial.
• Neo-adjuvant therapy in breast cancer.

  Bafaloukos D. Bafaloukos D. Ann Oncol. 2005;16 Suppl 2:ii174-81. doi: 10.1093/annonc/mdi704. Ann Oncol. 2005. PMID: 15958453 Review. No abstract available.